Russo Partners
Integrated communications for healthcare companies.
We focus exclusively on helping private and public healthcare companies to reach and influence their audiences.
From investors and business partners to regulatory agencies, physicians, payers and the general public. Since our founding as Noonan/Russo more than 30 years ago, we have been on a first-name basis with the people you need to be talking to.
Which means you should be talking to us.
Curing Corneal Blindness: Dr. Edward Holland on the Cincinnati Protocol
Behind the Byline: What Journalists Look for When Covering Biotech
Early Detection Matters: Insights into Alzheimer's Treatments and Caregiving
Why Baby Guts Hold the Key: Dr. Stephanie Culler on the Power of the Microbiome
Coya Therapeutics moves from IND clearance to Phase 2 in ALS research
From Songwriter to Patient Champion: Dana Parish on Giving Millions a Voice
Driving Innovation in Wound Healing: Inside BioStem with Jason Matuszewski
Rethinking Hydration with Microwearables: A Conversation with WearOptimo’s Mark Kendall
Solomon Wilcots Talks NFL, Pickleball, and the APP NYC Open on Fox 5’s “Sports Xtra”
Caregiving, Memory, and Hope: A Conversation with Novelist Muffy Walker
Investor Ready: Sara Jane Demy on Connection, Capital, and CEO Conversations
The Intersection of Sports and Health: Football Icons Shaun O’Hara, Ed McCaffrey, and Alex Smith
The Neuroscience Behind ALS Solutions: A Conversation with Dr. Shiran Zimri
From Research to Reality: Insights from Dr. Paul Wotton
David Bearss, CEO, Halia Therapeutics
Transforming Bone Marrow Transplants: Kevin Caldwell at Ossium Health
Jill Pellegrino, CEO of AutoCruitment
From Lab to Boardroom: The Leadership Edge’s Gaylene Xanthopoulos on CEO Strategies
Biotech Horizons: Industry Evolution, Q4 Outlook, and Key Catalysts with Graig Suvannavejh
Revolutionizing Medicine with Cell Therapy: Brian Culley, CEO of Lineage Cell Therapeutics
Pete O'Heeron, CEO of FibroBiologics
Rob Etherington, CEO of Clene Nanomedicine
BETx 2024: BioEngineering in Paris
Employee Engagement in BioTech and Pharma
Simon Arkell, Ryght
David Bearss, Halia Therapeutics
Sean Bohen, Olema Oncology
Gaumard Scientific's HAL® S5301 | Spectrum News 1 Southern California | 1/18/2022